Cellular b-2 microglobulin expression as a prognostic indicator in renal cell carcinoma

I. Levin; O. Kuperman; J. Goldstein; L. Neumann; S. Segal; J. Kaneti; L. Lismer; A. Machpud; B. Klein

doi:10.3109/02841869109088247

Cellular b-2 microglobulin expression as a prognostic indicator in renal cell carcinoma

I. Levin, O. Kuperman, J. Goldstein, L. Neumann, S. Segal, J. Kaneti, L. Lismer, A. Machpud, B. Klein

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

The expression of B-2 microglobulin (B-2M) on tumor cells and their normal cell counterparts in 39 patients with renal cell carcinoma was studied and correlated to tumor stage and survival. The median survival time of patients with localized disease (stage I) whose tumors expressed B-2M was 10.2 years while the median survival time for patients whose tumors did not express B-2M was only 3.6 years (p < 0.001). For patients with more advanced disease (stages II, 111, IV) whose tumors expressed B-2M, median survival time was 3.6 years compared to 2.0 years in patients whose tumors did not express B-2M, a non-significant difference. It is suggested that the tumor cell membrane expression of B-2M may serve as an indicator of good prognosis in early renal cell carcinoma.

Original language	English
Pages (from-to)	941-945
Number of pages	5
Journal	Acta Oncologica
Volume	30
Issue number	8
DOIs	https://doi.org/10.3109/02841869109088247
State	Published - 1 Jan 1991

Keywords

B-2 microglobulin
Renal cell carcinoma
Survival

ASJC Scopus subject areas

Hematology
Oncology
Radiology Nuclear Medicine and imaging

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/02841869109088247

Cite this

@article{6fa8b3d9a9b944d0b9a951d350ec63e3,

title = "Cellular b-2 microglobulin expression as a prognostic indicator in renal cell carcinoma",

abstract = "The expression of B-2 microglobulin (B-2M) on tumor cells and their normal cell counterparts in 39 patients with renal cell carcinoma was studied and correlated to tumor stage and survival. The median survival time of patients with localized disease (stage I) whose tumors expressed B-2M was 10.2 years while the median survival time for patients whose tumors did not express B-2M was only 3.6 years (p < 0.001). For patients with more advanced disease (stages II, 111, IV) whose tumors expressed B-2M, median survival time was 3.6 years compared to 2.0 years in patients whose tumors did not express B-2M, a non-significant difference. It is suggested that the tumor cell membrane expression of B-2M may serve as an indicator of good prognosis in early renal cell carcinoma.",

keywords = "B-2 microglobulin, Renal cell carcinoma, Survival",

author = "I. Levin and O. Kuperman and J. Goldstein and L. Neumann and S. Segal and J. Kaneti and L. Lismer and A. Machpud and B. Klein",

note = "Funding Information: This work was supported by The Rosen Foundation.",

year = "1991",

month = jan,

day = "1",

doi = "10.3109/02841869109088247",

language = "English",

volume = "30",

pages = "941--945",

journal = "Acta Oncologica",

issn = "0284-186X",

publisher = "Medical Journals Sweden AB",

number = "8",

}

TY - JOUR

T1 - Cellular b-2 microglobulin expression as a prognostic indicator in renal cell carcinoma

AU - Levin, I.

AU - Kuperman, O.

AU - Goldstein, J.

AU - Neumann, L.

AU - Segal, S.

AU - Kaneti, J.

AU - Lismer, L.

AU - Machpud, A.

AU - Klein, B.

N1 - Funding Information: This work was supported by The Rosen Foundation.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - The expression of B-2 microglobulin (B-2M) on tumor cells and their normal cell counterparts in 39 patients with renal cell carcinoma was studied and correlated to tumor stage and survival. The median survival time of patients with localized disease (stage I) whose tumors expressed B-2M was 10.2 years while the median survival time for patients whose tumors did not express B-2M was only 3.6 years (p < 0.001). For patients with more advanced disease (stages II, 111, IV) whose tumors expressed B-2M, median survival time was 3.6 years compared to 2.0 years in patients whose tumors did not express B-2M, a non-significant difference. It is suggested that the tumor cell membrane expression of B-2M may serve as an indicator of good prognosis in early renal cell carcinoma.

AB - The expression of B-2 microglobulin (B-2M) on tumor cells and their normal cell counterparts in 39 patients with renal cell carcinoma was studied and correlated to tumor stage and survival. The median survival time of patients with localized disease (stage I) whose tumors expressed B-2M was 10.2 years while the median survival time for patients whose tumors did not express B-2M was only 3.6 years (p < 0.001). For patients with more advanced disease (stages II, 111, IV) whose tumors expressed B-2M, median survival time was 3.6 years compared to 2.0 years in patients whose tumors did not express B-2M, a non-significant difference. It is suggested that the tumor cell membrane expression of B-2M may serve as an indicator of good prognosis in early renal cell carcinoma.

KW - B-2 microglobulin

KW - Renal cell carcinoma

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0026338911&partnerID=8YFLogxK

U2 - 10.3109/02841869109088247

DO - 10.3109/02841869109088247

M3 - Article

AN - SCOPUS:0026338911

SN - 0284-186X

VL - 30

SP - 941

EP - 945

JO - Acta Oncologica

JF - Acta Oncologica

IS - 8

ER -

Cellular b-2 microglobulin expression as a prognostic indicator in renal cell carcinoma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this